Mannitol therapy involves the intravenous administration of mannitol, a naturally occurring sugar alcohol, for a variety of therapeutic purposes. As an osmotic agent, mannitol creates a concentration gradient that draws fluid across semipermeable membranes, making it valuable in several critical care and surgical settings.
Mannitol acts as an osmotic diuretic. By increasing the osmolarity of the glomerular filtrate, it inhibits water reabsorption in the renal tubules, thereby increasing urine output and promoting the elimination of excess fluid and electrolytes.
This is one of the most common uses. Mannitol raises plasma osmolarity, creating an osmotic gradient that draws water from brain parenchyma into the intravascular space. This reduces cerebral edema and lowers intracranial pressure in conditions such as traumatic brain injury, stroke, and neurosurgical procedures.
In settings like rhabdomyolysis or contrast-induced nephropathy, mannitol helps maintain tubular flow and flush out toxic pigments or contrast media, potentially limiting renal tubular damage. It is often used prophylactically before contrast administration in high-risk patients.
For certain drug overdoses (e.g., barbiturates, salicylates, lithium) that are primarily renally excreted, mannitol-induced forced diuresis can accelerate clearance, though its use is now more selective and often replaced by other modalities.
Mannitol may be used as an adjunct during fluid resuscitation in DKA to promote diuresis and help correct electrolyte imbalances, though careful monitoring is essential.
During cardiac surgery, mannitol is sometimes added to the bypass circuit prime or given intravenously to protect renal function by maintaining urine output and reducing oxidative stress on the kidneys.
Mannitol is administered intravenously, typically as a 15–20% solution. Dosage varies by indication (e.g., 0.25–1 g/kg for ICP reduction). Continuous monitoring of:
is critical to avoid complications such as dehydration, hypernatremia, volume overload, or acute kidney injury from tubular obstruction.
Mannitol is contraindicated in anuria due to severe renal disease, active intracranial hemorrhage (except during craniotomy), severe pulmonary edema, and known hypersensitivity. Use with caution in heart failure and electrolyte imbalances.
Summary: Mannitol therapy is a versatile osmotic tool in critical care, neurosurgery, nephrology, and toxicology. Its safe and effective use requires precise indication, dosing, and vigilant monitoring of fluid, electrolyte, and renal parameters.